在临床早期的视觉安全风险评估工具
Kathrin Wawra-Hehenberger1, Vanessa Pencelli1, January Anne Pardo1
1CSL Behring, Marburg, Germany.
Contemporary clinical trials
|May 17, 2025
概括
定制的风险矩阵通过可视化安全风险和缓解效应,有助于早期临床开发. 该工具增强了多学科团队之间的积极风险管理和沟通.
科学领域:
- 药物监测和临床试验安全性
- 药物开发中的风险管理
背景情况:
- 动态安全风险评估是临床开发所有阶段的药监标准.
- 在早期临床试验中需要实用工具来主动评估安全风险.
研究的目的:
- 试点定制一个共同的风险矩阵,以便在临床开发早期主动评估安全风险.
- 评估针对多学科安全讨论的定制视觉工具的有用性.
主要方法:
- 将一个共同的风险矩阵定制为特定研究领域.
- 应用量身定制的矩阵来可视化已知的风险概况和预计的缓解效应.
- 在单个图表上开发双重可视化,显示风险定位和缓解影响.
主要成果:
- 量身定制的安全风险矩阵有效地可视化了预测的安全风险概况和缓解效应.
- 视觉工具在早期发展过程中促进了多学科团队之间的沟通和决策.
- 该矩阵为团队提供了一个实用的蓝图,以适应他们特定的研究维度.
结论:
- 定制的视觉风险矩阵是早期临床开发中主动安全风险管理的宝贵工具.
- 该工具通过提供风险概况和缓解策略的清晰快照来增强沟通和决策.
- 这种方法支持将实际的风险评估工具整合到现有的药监督过程中.
相关概念视频
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...


